Hoechst Marion Roussel Funds Outcomes Research

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 6
Volume 6
Issue 6

KANSAS CITY, Mo--Hoechst Marion Roussel is offering research grants totaling nearly $500,000 to fund health economics and outcomes studies through its 1997 ACCORD (A Company-wide Commitment to Outcomes Research and Development) program.

KANSAS CITY, Mo--Hoechst Marion Roussel is offering research grantstotaling nearly $500,000 to fund health economics and outcomes studiesthrough its 1997 ACCORD (A Company-wide Commitment to Outcomes Researchand Development) program.

Researchers and institutions interested in applying for grants can receivea program brochure and application form by calling ACCORD coordinator MaryMiller at 816-966-3780. The deadline for proposals is August 15, 1997.

Articles in this issue
Studies of Counselings' Impact on Survival Challenged
Telomerase Activity Potential Marker for Bladder Cancer
HIV Has Become a Specialty Disease, But One Open to the Well-Informed Generalist
Writing Genetic Testing Guidelines Complex Endeavor
AACR Meeting Sees Growth Spurt in Telomerase Research
DDT Appears to Activate Human Estrogen Receptors
Studies Highlight Role of bcl-2 Gene in Programmed Cell Death
Efficacy of BCG Maintenance in Bladder Cancer Is Confirmed
Surgery Seen as Adjunct to Chemo in Some Invasive Breast Cancers
Traveling Exhibit of Cancer Educational Resources
History of Substance Abuse Not a Barrier to Opioid Use
Support Program for Melanoma Patients Receiving Interferon
Taxol/Adriamycin as First-Line Metastatic Breast Cancer Therapy
New Cancer Websites, New Features Join the Information Highway
Dying in Hospital May Be Preferable to Dying at Home
Recent Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Generally, the communication in academic oncology institutions is favorable; however, when oncologists and pathologists become busy, specimens may be sent to reference laboratories.
Related Content
Findings from the 2025 World Conference on Lung Cancer reflected key updates in the management of NSCLC, SCLC, and other lung cancer types.

WCLC 2025: The Top 5 Takeaways Across Lung Cancer Care

Russ Conroy
September 12th 2025
Article

Findings from the 2025 World Conference on Lung Cancer reflected key updates in the management of NSCLC, SCLC, and other lung cancer types.

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

The second takeaway is that the type of responses and efficacy that we have seen with these combinations rival what we have in our standard of care armamentarium.

How Promising Are Immunotherapy Combos in Indolent Lymphoma?

Tim Cortese
September 12th 2025
Article

Lorenzo Falchi, MD, highlighted the most important considerations when using novel immunotherapy combination therapies for patients with indolent lymphoma.

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

Episode 13: Perspectives on Optimizing Community Care at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.

Understanding Predictive Markers Drives Ruxolitinib Usage in Myelofibrosis

Tim Cortese
September 12th 2025
Article

According to Francesca Palandri, MD, PhD, ruxolitinib will have a less significant effect in patients with myelofibrosis who have a cytopenic phenotype.

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

SC Amivantamab Consistent With IV Formulation in EGFR-Mutated NSCLC

Roman Fabbricatore
September 11th 2025
Article

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.